APO Research
Talk to an analyst

APO RESEARCH · REPORT

Insulin Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Insulin Biologics and Biosimilars Market Analysis and Forecast 2026-2032

21 December 2025198 pages

Choose your research edition.

Industry ResearchInsulin Biologics and Biosimilars Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Insulin Biologics and Biosimilars Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Insulin Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Insulin Biologics and Biosimilars Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Insulin Biologics and Biosimilars Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Insulin Biologics and Biosimilars market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Insulin Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Insulin Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Insulin Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Insulin Biologics and Biosimilars is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Insulin Biologics and Biosimilars include Tonghua Dongbao, Sanofi, Novo Nordisk, Eli Lilly, Wockhardt, United Laboratory, Geropharm, Gan&Lee and Biocon, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Insulin Biologics and Biosimilars, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Insulin Biologics and Biosimilars, also provides the revenue of main regions and countries. Of the upcoming market potential for Insulin Biologics and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Insulin Biologics and Biosimilars revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Insulin Biologics and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Insulin Biologics and Biosimilars revenue, projected growth trends, production technology, application and end-user industry.

Insulin Biologics and Biosimilars Segment by Company

Tonghua Dongbao

Sanofi

Novo Nordisk

Eli Lilly

Wockhardt

United Laboratory

Geropharm

Gan&Lee

Biocon

Insulin Biologics and Biosimilars Segment by Type

Insulin Biologics

Insulin Biosimilars

Insulin Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Insulin Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Insulin Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Insulin Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Insulin Biologics and Biosimilars company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Insulin Biologics and Biosimilars revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Insulin Biologics Major Player Table 3. Insulin Biosimilars Major Player Table 4. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Retail Pharmacy Major Player Table 7. Other Major Player Table 8. Insulin Biologics and Biosimilars Industry Trends Table 9. Insulin Biologics and Biosimilars Industry Drivers Table 10. Insulin Biologics and Biosimilars Industry Opportunities and Challenges Table 11. Insulin Biologics and Biosimilars Industry Restraints Table 12. Global Insulin Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Insulin Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Insulin Biologics and Biosimilars Market Share by Region (2021-2026) Table 15. Global Insulin Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Insulin Biologics and Biosimilars Market Share by Region (2027-2032) Table 17. Global Insulin Biologics and Biosimilars Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2021-2026) Table 19. Global Insulin Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Insulin Biologics and Biosimilars Key Players Headquarters & Area Served Table 21. Global Insulin Biologics and Biosimilars Players, Product Type & Application Table 22. Global Insulin Biologics and Biosimilars Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Insulin Biologics and Biosimilars by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Insulin Biologics and Biosimilars Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 29. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 30. Global Insulin Biologics and Biosimilars Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 34. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 35. Tonghua Dongbao Company Information Table 36. Tonghua Dongbao Business Overview Table 37. Tonghua Dongbao Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio Table 39. Tonghua Dongbao Recent Development Table 40. Sanofi Company Information Table 41. Sanofi Business Overview Table 42. Sanofi Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sanofi Insulin Biologics and Biosimilars Product Portfolio Table 44. Sanofi Recent Development Table 45. Novo Nordisk Company Information Table 46. Novo Nordisk Business Overview Table 47. Novo Nordisk Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio Table 49. Novo Nordisk Recent Development Table 50. Eli Lilly Company Information Table 51. Eli Lilly Business Overview Table 52. Eli Lilly Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Eli Lilly Insulin Biologics and Biosimilars Product Portfolio Table 54. Eli Lilly Recent Development Table 55. Wockhardt Company Information Table 56. Wockhardt Business Overview Table 57. Wockhardt Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Wockhardt Insulin Biologics and Biosimilars Product Portfolio Table 59. Wockhardt Recent Development Table 60. United Laboratory Company Information Table 61. United Laboratory Business Overview Table 62. United Laboratory Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. United Laboratory Insulin Biologics and Biosimilars Product Portfolio Table 64. United Laboratory Recent Development Table 65. Geropharm Company Information Table 66. Geropharm Business Overview Table 67. Geropharm Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Geropharm Insulin Biologics and Biosimilars Product Portfolio Table 69. Geropharm Recent Development Table 70. Gan&Lee Company Information Table 71. Gan&Lee Business Overview Table 72. Gan&Lee Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Gan&Lee Insulin Biologics and Biosimilars Product Portfolio Table 74. Gan&Lee Recent Development Table 75. Biocon Company Information Table 76. Biocon Business Overview Table 77. Biocon Insulin Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Biocon Insulin Biologics and Biosimilars Product Portfolio Table 79. Biocon Recent Development Table 80. North America Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Insulin Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Insulin Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Insulin Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Insulin Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 94. China Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 95. China Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 96. China Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 97. China Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Insulin Biologics and Biosimilars Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Insulin Biologics and Biosimilars Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Insulin Biologics and Biosimilars Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Insulin Biologics and Biosimilars Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Insulin Biologics and Biosimilars Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Insulin Biologics and Biosimilars Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Insulin Biologics and Biosimilars Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Insulin Biologics and Biosimilars Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Insulin Biologics and Biosimilars Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Insulin Biologics and Biosimilars Image Figure 2. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Insulin Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 4. Insulin Biologics Image Figure 5. Insulin Biosimilars Image Figure 6. Global Insulin Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Insulin Biologics and Biosimilars Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Retail Pharmacy Image Figure 10. Other Image Figure 11. Global Insulin Biologics and Biosimilars Market Size (US$ Million) & (2021-2032) Figure 12. Global Insulin Biologics and Biosimilars Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Insulin Biologics and Biosimilars Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Insulin Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Insulin Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Insulin Biologics and Biosimilars Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 19. Global Insulin Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 22. North America Insulin Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 24. North America Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 25. North America Insulin Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 26. United States Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Insulin Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 31. Europe Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 32. Europe Insulin Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 33. Germany Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Insulin Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 43. China Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 44. Asia Insulin Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 46. Asia Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 47. Asia Insulin Biologics and Biosimilars Revenue Share by Region (2021-2032) Figure 48. Japan Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Insulin Biologics and Biosimilars Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032) Figure 56. SAMEA Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032) Figure 57. SAMEA Insulin Biologics and Biosimilars Revenue Share by Country (2021-2032) Figure 58. Brazil Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Insulin Biologics and Biosimilars Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Insulin Biologics
  • Insulin Biosimilars
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Tonghua Dongbao
  • Sanofi
  • Novo Nordisk
  • Eli Lilly
  • Wockhardt
  • United Laboratory
  • Geropharm
  • Gan&Lee
  • Biocon

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Insulin Biologics and Biosimilars Market by Type
  3. 1.2.1 Global Insulin Biologics and Biosimilars Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Insulin Biologics
  5. 1.2.3 Insulin Biosimilars
  6. 1.3 Insulin Biologics and Biosimilars Market by Application
  7. 1.3.1 Global Insulin Biologics and Biosimilars Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Insulin Biologics and Biosimilars Market Dynamics
  1. 2.1 Insulin Biologics and Biosimilars Industry Trends
  2. 2.2 Insulin Biologics and Biosimilars Industry Drivers
  3. 2.3 Insulin Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Insulin Biologics and Biosimilars Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Insulin Biologics and Biosimilars Market Perspective (2021-2032)
  2. 3.2 Global Insulin Biologics and Biosimilars Growth Trends by Region
  3. 3.2.1 Global Insulin Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Insulin Biologics and Biosimilars Market Size by Region (2021-2026)
  5. 3.2.3 Global Insulin Biologics and Biosimilars Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Insulin Biologics and Biosimilars Revenue by Players
  2. 4.1.1 Global Insulin Biologics and Biosimilars Revenue by Players (2021-2026)
  3. 4.1.2 Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Insulin Biologics and Biosimilars Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Insulin Biologics and Biosimilars Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Insulin Biologics and Biosimilars Key Players Headquarters & Area Served
  7. 4.4 Global Insulin Biologics and Biosimilars Players, Product Type & Application
  8. 4.5 Global Insulin Biologics and Biosimilars Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Insulin Biologics and Biosimilars Market CR5 and HHI
  11. 4.6.3 2025 Insulin Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
5 Insulin Biologics and Biosimilars Market Size by Type
  1. 5.1 Global Insulin Biologics and Biosimilars Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 5.3 Global Insulin Biologics and Biosimilars Revenue Market Share by Type (2021-2032)
6 Insulin Biologics and Biosimilars Market Size by Application
  1. 6.1 Global Insulin Biologics and Biosimilars Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  3. 6.3 Global Insulin Biologics and Biosimilars Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Tonghua Dongbao
  2. 7.1.1 Tonghua Dongbao Company Information
  3. 7.1.2 Tonghua Dongbao Business Overview
  4. 7.1.3 Tonghua Dongbao Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Tonghua Dongbao Insulin Biologics and Biosimilars Product Portfolio
  6. 7.1.5 Tonghua Dongbao Recent Developments
  7. 7.2 Sanofi
  8. 7.2.1 Sanofi Company Information
  9. 7.2.2 Sanofi Business Overview
  10. 7.2.3 Sanofi Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Insulin Biologics and Biosimilars Product Portfolio
  12. 7.2.5 Sanofi Recent Developments
  13. 7.3 Novo Nordisk
  14. 7.3.1 Novo Nordisk Company Information
  15. 7.3.2 Novo Nordisk Business Overview
  16. 7.3.3 Novo Nordisk Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novo Nordisk Insulin Biologics and Biosimilars Product Portfolio
  18. 7.3.5 Novo Nordisk Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Insulin Biologics and Biosimilars Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Wockhardt
  26. 7.5.1 Wockhardt Company Information
  27. 7.5.2 Wockhardt Business Overview
  28. 7.5.3 Wockhardt Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Wockhardt Insulin Biologics and Biosimilars Product Portfolio
  30. 7.5.5 Wockhardt Recent Developments
  31. 7.6 United Laboratory
  32. 7.6.1 United Laboratory Company Information
  33. 7.6.2 United Laboratory Business Overview
  34. 7.6.3 United Laboratory Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 7.6.4 United Laboratory Insulin Biologics and Biosimilars Product Portfolio
  36. 7.6.5 United Laboratory Recent Developments
  37. 7.7 Geropharm
  38. 7.7.1 Geropharm Company Information
  39. 7.7.2 Geropharm Business Overview
  40. 7.7.3 Geropharm Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Geropharm Insulin Biologics and Biosimilars Product Portfolio
  42. 7.7.5 Geropharm Recent Developments
  43. 7.8 Gan&Lee
  44. 7.8.1 Gan&Lee Company Information
  45. 7.8.2 Gan&Lee Business Overview
  46. 7.8.3 Gan&Lee Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Gan&Lee Insulin Biologics and Biosimilars Product Portfolio
  48. 7.8.5 Gan&Lee Recent Developments
  49. 7.9 Biocon
  50. 7.9.1 Biocon Company Information
  51. 7.9.2 Biocon Business Overview
  52. 7.9.3 Biocon Insulin Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Biocon Insulin Biologics and Biosimilars Product Portfolio
  54. 7.9.5 Biocon Recent Developments
8 North America
  1. 8.1 North America Insulin Biologics and Biosimilars Revenue (2021-2032)
  2. 8.2 North America Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 8.2.1 North America Insulin Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 8.2.2 North America Insulin Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 8.3 North America Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 8.4 North America Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 8.4.1 North America Insulin Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 8.4.2 North America Insulin Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 8.5 North America Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 8.6 North America Insulin Biologics and Biosimilars Revenue by Country
  11. 8.6.1 North America Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Insulin Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 8.6.3 North America Insulin Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Insulin Biologics and Biosimilars Revenue (2021-2032)
  2. 9.2 Europe Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 9.2.1 Europe Insulin Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 9.2.2 Europe Insulin Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 9.3 Europe Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 9.4 Europe Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 9.4.1 Europe Insulin Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 9.4.2 Europe Insulin Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 9.5 Europe Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 9.6 Europe Insulin Biologics and Biosimilars Revenue by Country
  11. 9.6.1 Europe Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Insulin Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 9.6.3 Europe Insulin Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Insulin Biologics and Biosimilars Revenue (2021-2032)
  2. 10.2 China Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 10.2.1 China Insulin Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 10.2.2 China Insulin Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 10.3 China Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 10.4 China Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 10.4.1 China Insulin Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 10.4.2 China Insulin Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 10.5 China Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Insulin Biologics and Biosimilars Revenue (2021-2032)
  2. 11.2 Asia Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 11.2.1 Asia Insulin Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 11.2.2 Asia Insulin Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 11.3 Asia Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 11.4 Asia Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 11.4.1 Asia Insulin Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 11.4.2 Asia Insulin Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 11.5 Asia Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 11.6 Asia Insulin Biologics and Biosimilars Revenue by Country
  11. 11.6.1 Asia Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Insulin Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 11.6.3 Asia Insulin Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Insulin Biologics and Biosimilars Revenue (2021-2032)
  2. 12.2 SAMEA Insulin Biologics and Biosimilars Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Insulin Biologics and Biosimilars Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Insulin Biologics and Biosimilars Revenue by Type (2027-2032)
  5. 12.3 SAMEA Insulin Biologics and Biosimilars Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Insulin Biologics and Biosimilars Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Insulin Biologics and Biosimilars Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Insulin Biologics and Biosimilars Revenue by Application (2027-2032)
  9. 12.5 SAMEA Insulin Biologics and Biosimilars Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Insulin Biologics and Biosimilars Revenue by Country
  11. 12.6.1 SAMEA Insulin Biologics and Biosimilars Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Insulin Biologics and Biosimilars Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Insulin Biologics and Biosimilars Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst